Interim Report Perbio Science AB January - June 2003

Interim Report Perbio Science AB January - June 2003 Healthy sales growth impacted by weak US dollar · Net sales were SEK 1,033 (1,108) million which, as a result of the weak US dollar, was a decline of 7 percent. In dollar terms sales increased 15 percent to USD 124.2 (108.4) million · Gross margin improved to 46.6 percent (45.9 percent) · Profit after financial items was SEK 171 (190) million, a decline of 10 percent, but rose 11 percent in US dollars to USD 20.6 (18.6) million · Earnings per share after full dilution declined 11 percent to SEK 2.77 (3.12) · Public offer from Fisher Scientific International Inc. to purchase for cash all outstanding shares and warrants granted under the 1999 program for SEK 142.50 per share and SEK 93.50 per warrant was made. The offer will be open until August 14 Bioresearch Division · Sales were up 3 percent in US dollar · The European market continues to register the strongest sales development · Operating margin was reduced to 17.4 percent (20.4 percent) mainly due to non-recurring license revenue in the first half of 2002 Cell Culture Division · Sales were up 17 percent in US dollar · BioProcess Containers (BPC) showed continued healthy growth · Operating margin remained unchanged at 17.3 percent (17.3 percent) Medical Device Division · Strong growth continued, sales were up 25 percent in SEK · Operating margin rose to 23.4 percent (21.3 percent) Helsingborg, 1 August 2003 The Board of Perbio Science AB (publ.) Information on Perbio Science CEO Leland Foster phone +1 435 757 6432 CFO Claes Wenthzel phone +46 42 26 90 92 or +46 70 862 01 22 More information on Perbio Science can be found on the company's website at www.perbio.com Perbio Science AB (publ.) is a listed Swedish biotechnology company with research institutes, pharmaceutical companies and diagnostics companies as its customers. The USA accounts for the bulk of its business. Perbio Science supplies products, systems and services for the study and production of proteins, and develops products in the Bioresearch, Cell Culture and Medical Device fields. The group has 1,353 employees and offices in Sweden, the USA and a number of other countries. Its head office is in Helsingborg, Sweden. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/08/01/20030801BIT00120/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/08/01/20030801BIT00120/wkr0002.pdf The full report